Apogee Therapeutics, Inc.

Apogee Therapeutics, Inc.

APGE·NASDAQ

$84.19

+3.0%
HealthcareBiotechnology

Apogee Therapeutics, Inc., through its subsidiary, operates as a biotechnology company that develops biologics for the treatment of atopic dermatitis (AD), chronic obstructive pulmonary disease (COPD), and related inflammatory and immunology indications. The company primarily develops APG777, a subcutaneous (SQ) extended half-life monoclonal antibody (mAb) for AD; and APG808, an SQ extended half-life mAb for COPD. Its earlier-stage programs include APG990, an SQ extended half-life mAb for the treatment of AD; and APG222, an extended half-life SQ antibodies for AD. The company was founded in 2022 and is based in Waltham, Massachusetts.

At a Glance

Live Snapshot
Market Cap$5.21B
EPS-4.2200
P/E Ratio-19.95
Earnings Date08/10/2026

apge

Total Equity

Last Annual Value

903.88M

3-Year CAGR

85%

5-Year CAGR

45%

10-Year CAGR

20%

Apogee Therapeutics, Inc.

Apogee Therapeutics, Inc. Competitors Analysis of Total Equity

APGE · NASDAQ
CompanyTotal Equity
CAGR 3Y
CAGR 5Y
CAGR 10Y
903.88M
33.5%N/AN/A 
1.00B
-7.1%5.5%N/A
-73.00M
N/AN/AN/A
752.60M
59.7%79.6%N/A
CELC logo
Celcuity Inc.
NASDAQ:CELC
100.56M
-10.4%7.9%33.5%
739.83M
28.9%N/AN/A
450.12M
41.9%90.8%62.8%
Apogee Therapeutics, Inc.

Apogee Therapeutics, Inc. Fair Value Envelope

APGE · NASDAQ

Our analysis suggests that APGE has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $84.19, this represents a potential HIDDEN relative to our calculated worth for Apogee Therapeutics, Inc..

Intrinsic Value
Current Price: $84.19